“J&J Results Expected To Be Pressured By Generics” (Wall Street Journal)
Healthcare products giant Johnson & Johnson (JNJ) is expected to report moderately lower third-quarter earnings Tuesday, due in part to the loss of patent protection on such top-grossing drugs as Risperdal and Topamax.
“Sanofi, Merck Among Global Bidders for iNova, Review Reports “ (Bloomberg)
Sanofi-Aventis SA and Merck KGaA are among international drugmakers expected to bid for iNova Pharmaceuticals Pty Ltd., the Australian Financial Review said, citing unidentified analysts.
“Merck-dumped Paratek Woos Novartis: $485M Antibiotic Deal” (BioWorld)
Privately held Paratek Pharmaceuticals Inc. has found another partner to help develop its antibiotic PTK 0796 for life-threatening infections, this time joining with Swiss drugmaker Novartis AG in a deal valued at up to $485 million.
SUBSCRIBE